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Background. Yellow fever vaccine (17DV) has been investigated incompletely in human immunodeficiency
virus (HIV)–infected patients, and adequate immunogenicity and safety are of concern in this population.
Methods. In the Swiss HIV Cohort Study, we identified 102 patients who received 17DV while they were HIV
infected. We analyzed neutralization titers (NTs) after 17DV administration using the plaque reduction neutrali-
zation test. NTs of 1:10 were defined as reactive, and those of 1:!10 were defined as nonreactive, which was
considered to be nonprotective. The results were compared with data for HIV-uninfected individuals. Serious
adverse events were defined as hospitalization or death within 6 weeks after receipt of 17DV.
Results. At the time of 17DV administration, the median CD4 cell count was 537 cells/mm3 (range, 11–1730
cells/mm3), and the HIV RNA level was undetectable in 41 of 102 HIV-infected patients. During the first year
after vaccination, fewer HIV-infected patients (65 [83%] of 78; ) than HIV-uninfected patients revealedPp .01
reactive NTs, and their NTs were significantly lower ( ) than in HIV-uninfected individuals. Eleven patientsP ! .001
with initially reactive NTs lost these reactive NTs 5 years after vaccination. Higher NTs during the first year after
vaccination were associated with undetectable HIV RNA levels, increasing CD4 cell count, and female sex. We
found no serious adverse events after 17DV administration among HIV-infected patients.
Conclusion. Compared with HIV-uninfected individuals, HIV-infected patients respond to 17DV with lower
reactive NTs, more often demonstrate nonprotective NTs, and may experience a more rapid decline in NTs during
follow-up. Vaccination with 17DV appears to be safe in HIV-infected individuals who have high CD4 cell counts,
although rate of serious adverse events of up to 3% cannot be excluded.
Yellow fever is a severe arthropod-borne hemorrhagic
fever that is endemic in many countries in sub-Saharan
Africa and South America, with an estimated 200,000
cases occurring annually and a case-fatality rate of
20%–50% [1, 2]. It can be effectively prevented with
administration of the live, attenuated 17D yellow fever
vaccine (17DV) [3]. The prevalence of HIV infection
is high in many countries where yellow fever is endemic.
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Data about the immunogenicity and safety of 17DV
vaccination in HIV-infected individuals are limited to
case reports or small series [4–11]. In areas where out-
breaks of yellow fever occur, mass immunization
against yellow fever—including immunization of many
HIV-infected individuals—is problematic without data
about safety and immunogenicity. In addition to this
public health problem in countries with epidemic yel-
low fever, administration of 17DV to HIV-infected trav-
elers from western countries is of concern: since the
introduction of combination antiretroviral therapy
(cART), the health and immune status of HIV-infected
patients have improved, resulting in an increase in
travel. In the Swiss HIV Cohort Study (SHCS), the
percentage of HIV-infected individuals who traveled to
tropical countries at least once increased from 13%
during 1988–1999 [12] to 29% in the current study. In
a single-center survey, 55% of HIV-infected travelers
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Figure 1. Study design. Only the 102 patients who were vaccinated
after HIV infection had been diagnosed were included in the study. Pa-
tients with reactive neutralization titers (NTs) were included in11 category
of this figure. Patients with nonreactive NTs are shown only in the time
category, when the first nonreactive NT had occurred. 17DV, yellow fever
vaccination; YPV, years after vaccination.
had visited countries where yellow fever is endemic [13].
Although 17DV is generally considered to be safe, rare severe
adverse events (SAEs), including yellow fever vaccine–associ-
ated viscerotropic and neurotropic disease, and deaths have
occurred [14–19]. The incidence of SAEs after 17DV admin-
istration in HIV-infected patients is unknown. Thus far, to our
knowledge, only 1 fatal case of neurotropic disease has been
reported after administration of 17DV to an HIV-infected pa-
tient [6].
We investigated the immunogenicity and the safety of 17DV
in HIV-infected patients in the SHCS for the following reasons:
(1) to determine the primary immune response, (2) to observe
the antibody titer in HIV-infected individuals, (3) to investigate
predictive factors of adequate antibody response to 17DV, (4)
to compare the yellow fever immune response in HIV-infected
versus HIV-uninfected individuals, and (5) to analyze the in-
cidence of SAE after administration of 17DV in HIV-infected
patients. We hypothesized that, in the era of cART, the im-
munogenicity and safety of 17DV in HIV-infected individuals
would be similar to that in the general population of travelers.
METHODS
Patients. The SHCS (http://www.shcs.ch) is a prospective co-
hort study based on 7 health care centers in Switzerland [20].
Information is collected according to standardized criteria on
structured forms at enrolment and at 6 monthly follow-up visits
and includes information about travels to tropical countries.
At these occasions, plasma samples are obtained and stored at
70C for every patient. All participants provide written in-
formed consent. SHCS has been approved by all appropriate
local ethics committees.
Four of the 7 SHCS centers participated in the present study.
We identified SHCS participants who had reported a journey
to a tropical destination during the period 1 January 1996
through 31 August 2005. These individuals were asked either
during consultation, by phone, or on questionnaires or chart
reviews about their travel destinations in the past and whether
they had received 17DV. In the case of a reported travel to a
country where yellow fever is endemic, the vaccine certificate
and the medical charts were checked for 17DV, and travelers
who had received at least 1 dose of 17DV were enrolled in the
study. Patients were grouped according to whether 17DV had
been administered before or after diagnosis of HIV infection.
Patients who had been vaccinated 1 year before documen-
tation of HIV infection were classified as being HIV infected
unless there was documented seroconversion within that year.
The day that 17DV was administered was the baseline time
point. If a patient had received 11 dose of 17DV, the date of
the last vaccination was determined as baseline.
To define predictors to vaccine response, baseline character-
istics were collected from the SHCS database and medical
charts. Baseline laboratory markers within 1 year before or after
17DV administration were accepted. Medical history was
checked for concomitant immunosuppressive medication at the
time and until one month after 17DV. The vaccination card
was checked for other concomitant live vaccines given at the
time until 1 month after receipt of 17DV. The data for these
HIV-infected vaccinees were compared with serologic data for
a group of 209 HIV-uninfected individuals who had received
17DV and who were investigated in 1999 with the same lab-
oratory method [21]. The raw data from this comparison group
were available for the analysis. This group did not differ in age
from our study population. Additional characteristics were not
available for this comparison group.
Determination of yellow fever neutralization titer (NT).
The analysis of human plasma or serum for the yellow fever
NT was performed at the Robert Koch Institute (Berlin, Ger-
many) using the plaque reduction neutralization test, as de-
scribed elsewhere [22]. All plasma samples were assayed twice
and in 2-fold dilutions (range, 1:10–1:320 NTs for the final
dilutions). The plaques caused by lysis of infected cells were
counted, and the 90% NT was calculated. According to the
study by Niedrig et al. [21], NTs of 1:10 are defined as re-
active, and those of 1:!10 are defined as nonreactive, which
was considered to be nonprotective. The decrease in NTs was
modelled as log10 of the reciprocal NT over time. NTs were
analyzed in the following defined time periods: (1) for the
primary immune response, between 1 month and 1 year after
vaccination; (2) 1–10 years after vaccination; and (3) 110 years
after vaccination, if the corresponding plasma sample was avail-
able (figure 1). In the comparison group of HIV-uninfected
individuals, serum samples were collected only once per in-
dividual (range, 0.01–37.5 years after vaccination) [21].
Safety. SAE was defined as hospitalization or death 6
weeks after receipt of 17DV, with no explanation other than
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Table 1. Baseline characteristics of study patients.
Characteristic
Value
(n p 102)
Age, median years (IQR) 34.7 (28.1–41.5)
Female sex 48 (47)
Region of origin
Europe or North America 59 (58)
Sub-Saharan Africa 41 (40)
South America 1 (1)
Other 1 (1)
Mode of HIV transmission
Heterosexual sexual contact 63 (62)
Male-male sexual contact 22 (22)
Injection drug use 8 (8)
Other or unknown 9 (9)
CDC HIV infection category
A 71 (70)
B 24 (24)
C 7 (7)
CD4 cell count
Median cells/mm3 (range) 512 (368–664)
Missing data 16 (16)
!200 cells/mm3 7 (7)
200–349 cells/mm3 13 (13)
350–499 cells/mm3 22 (22)
1500 cells/mm3 44 (43)
Nadir CD4 cell count
Median cells/mm3 (IQR) 280 (163–469)
Missing data 15 (15)
HIV RNA level !50 copies/mL, n/N (%) 41/84 (48)
Missing data on HIV RNA level 18 (18)
Receipt of triple-drug ART 41 (40)
Chronic hepatitis B or C 19 (19)
Interval between receipt of 17DV and
diagnosis of HIV infection, median
years (IQR) 3.0 (0.8–8.4)
Receipt of 17DV 2 times 17 (17)
NOTE. Data are no. (%) of patients, unless otherwise indicated. ART, an-
tiretroviral therapy; CDC, Centers for Disease Control and Prevention; IQR,
interquartile range; 17DV, yellow fever vaccine.
vaccination. The medical charts for all deceased patients during
the study period were checked for any correlation of death to
17DV receipt or any SAE. In addition, the Swiss vaccination
surveillance system was queried for any SAEs that occurred
after 17DV administration in HIV-infected individuals.
Statistical analysis. Univariable analysis was performed
using nonparametric tests for numerical variables and the x2
test for categorical variables. Logistic regression was used for
univariable and multivariable analysis to investigate parameters
associated with nonreactive versus reactive NTs during the first
year after vaccination. Linear regression was used for univar-
iable and multivariable analysis of parameters associated with
the value of NT. The multivariable regression models included
HIV RNA levels !50 copies/mL as a binary variable and CD4
cell count at time of receipt of 17DV, age, sex, chronic hepatitis
B or C virus infection, and receipt of yellow fever vaccine at
least once before the current vaccination. Square-rooted CD4
cell counts were implemented in the regression models. Anal-
yses were conducted using Stata software, version 9.0 (Stata).
RESULTS
In the study period, 2648 (29%) of the 9181 SHCS participants
traveled at least once to a tropical country. Among those, 868
travelers (33%) were observed at the 4 investigating centers.
One hundred seventy-two travelers (20%) were excluded be-
cause no reliable information was available, and 696 travelers
(26% of the SHCS travelers) were evaluated for 17DV. A total
of 174 recipients of 17DV were identified: 102 patients had
received 17DV after and 72 had received 17DV before HIV
infection was documented (figure 1). Unless otherwise indi-
cated, we will focus below on the 102 patients who received
17DV while being HIV infected.
Characteristics of the 102 HIV-infected patients at the time
of 17DV are shown in table 1. Study patients were more likely
to be female, black, and originally from sub-Saharan Africa and
were less likely to have chronic hepatitis B or C and injection
drug abuse as a mode of HIV transmission, compared with
nontravelers in the SHCS. None of the study participants had
taken immunosuppressive therapy at the time of 17DV vac-
cination. The majority of the patients (83%) were primary
vaccinees, and 71% had been vaccinated with the 17DV man-
ufactured by Aventis Pasteur (Stamaril). Plasma or serum spec-
imens for NT analysis were available for 78 patients within 1
year after vaccination, for 70 patients 1–10 years after vacci-
nation, and for 11 patients 110 years after vaccination (figure
1). Among HIV-uninfected persons, serum samples were avail-
able for 66 individuals within 1 year after vaccination, for 92
individuals 1–10 years after vaccination, and for 51 individuals
110 years after vaccination.
Immunogenicity. The NT decay pattern of our study pop-
ulation (figure 2) was similar to that of HIV-uninfected indi-
viduals. However, within the first year after vaccination, a sig-
nificantly greater proportion of HIV-infected patients (13
[17%] of 78) had nonreactive NTs, compared with HIV-un-
infected vaccinees, for whom nonreactive NTs were found in
2 (3%) of 66 individuals (figure 3). An even higher proportion
of persons with nonreactive NTs (19%) was seen among the
63 patients who had been vaccinated for the first time against
yellow fever ( , compared with HIV-uninfected indi-Pp .004
viduals). The proportion of HIV-infected patients with non-
reactive NTs increased from 17% to 23% during the time period
of 1–10 years after vaccination (figure 3). In addition, HIV-
infected patients had significantly lower NTs than did HIV-
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Figure 2 All neutralization titers (NTs) for patients vaccinated against yellow fever after diagnosis of HIV infection, with the fractional polynomial
prediction line. NTs measurements were performed at least once; in some patients, they were performed up to 4 times.
Figure 3. Neutralization titer (NT) 1 year (upper panel) and 1–10
years after (lower panel) yellow fever vaccination.
uninfected individuals, both within the first year after vacci-
nation and thereafter (figure 4).
Baseline parameters associated with primary immune
response. The 78 patients who underwent NT evaluations
during the first year after receipt of 17DV were analyzed for
baseline parameters predicting vaccination response. In these
patients, the median baseline CD4 cell count was 496 cells/mm3
(range, 72–1730 cells/mm3). More than three-quarters (77%)
had CD4 cell counts 1350 cells/mm3, and only 6 of the 78
patients had CD4 cell counts !200 cells/mm3. In 37 patients
(48%), HIV RNA levels were !50 copies/mL. There was no
statistically significant predictor of reactive ( ) versusnp 65
nonreactive NT ( ); however, patients who were receivingnp 13
successful cART had an OR of 2.5 (95% CI, 0.7–8.8; ).Pp .17
Of the 6 vaccinated patients with CD4 cell counts !200 cells/
mm3, 2 did not develop reactive NTs.
Suppressed plasma HIV RNA levels, higher CD4 cell counts,
female sex, absence of chronic hepatitis, and older age had a
statistically significant association or showed a trend toward
higher NTs during the first year after vaccination (table 2). In
addition, suppressed HIV RNA level and higher CD4 cell count
at the time of first NT determination were associated with a
better primary immunological response ( and .02,Pp .006
respectively).
“Losers and winners.” Eleven patients who received 17DV
after HIV infection had been diagnosed initially had reactive
NTs but were revealed to have nonreactive NTs !5 years after
vaccination (median, 1.8 years after vaccination; range, 0.9–5.1
years after vaccination). Only 1 of these patients had an un-
detectable HIV RNA level at the time of receipt of 17DV, and
the HIV RNA level was not suppressed in 8 patients when the
follow-up nonreactive NTs were determined.
Four of the 102 HIV-infected patients had nonreactive NTs
at first analysis but were revealed to have reactive NTs during
follow-up. This phenomenon was also seen in 6 patients who
had received 17DV before HIV infection was documented.
Seven of these 10 patients had detectable HIV RNA levels
(range, 439–894,246 copies/mL) at the time that nonreactive
NTs were noted. At the time that reactive NTs were noted
during follow-up, however, 5 of these 7 patients had unde-
tectable HIV RNA levels.
HIV/AIDS • CID 2009:48 (1 March) • 663
Figure 4. Value of neutralization titer (NT) 1 year (upper panel) and
1–10 years after (lower panel) yellow fever vaccination. Horizontal line,
median value.
Safety. We found no SAEs related to 17DV administration
in the 102 individuals who were vaccinated after HIV had been
diagnosed, corresponding to an estimated rate of 0%, with an
upper 95% confidence limit of 2.9%. The 48 deaths that oc-
curred during the study period in the traveling population,
including the 3 deaths in the 17DV-vaccinated population, were
clearly not associated with 17DV. No SAEs related to 17DV
among HIV-infected individuals were reported to the Swiss
vaccination surveillance program.
DISCUSSION
In the current analysis, we show that the immunogenicity of
17DV is impaired in HIV-infected individuals. We did not ob-
serve SAEs associated with the vaccine in our study population
of patients, who predominantly had mild to moderate
immunodeficiency.
Immunogenicity of 17DV. Immune response to killed or
inactivated vaccines is impaired in HIV-infected patients, es-
pecially if their CD4 cell counts are !350 cells/mm3 [23–28].
However, data regarding immune response to live, attenuated
vaccines are limited. Asymptomatic HIV-infected children re-
ceiving cART demonstrated an adequate immune response to
rubella, measles, and mumps vaccination [29, 30].
Impaired vaccine response may be explained by the aberrant
activation of B cells in replicating HIV infection [31], an im-
paired T-helper response, and cellular mediated immunity [22].
By reducing immune activation and improving T-helper re-
sponse, cART may be associated with improved vaccine re-
sponse [32].
In HIV-infected patients, the immunogenicity of 17DV has
been reported only in small series, and the results are contro-
versial. Protective yellow fever NTs were found in all of 12 HIV-
infected individuals with CD4 cell counts of 240–1300 cells/
mm3 [9]. By contrast, in the era before introduction of cART,
reactive antibody titers were found in 27 of 31 HIV-infected
adults with CD4 cell counts 1200 cells/mm3 and in only 3 of
18 vaccinated, asymptomatic HIV-infected children [4, 8]. In
a recently published study, 4 of 11 HIV-infected travelers with
CD4 cell counts 1200 cells/mm3 had nonreactive NTs after
receipt of primary 17DV, and all 4 patients showed reactive
NTs after receipt of a second dose of 17DV [11].
In our study, patients who had been vaccinated after they
had learned of their HIV seropositivity were less likely to show
a reactive immune response to 17DV1 year after vaccination,
and their reactive NTs were lower than in HIV-uninfected vac-
cinees. In addition, 11 patients with initially reactive NTs had
nonreactive NTs in later samples, pointing toward a more pro-
nounced decline. One to 10 years after vaccination, the NTs in
HIV-infected individuals were significantly lower than in HIV-
uninfected individuals, and the proportion of individuals who
lacked a reactive immune response to 17DV (23%) was double
that of HIV-uninfected vaccinees. This difference did not
achieve full statistical significance ( ), probably because,Pp .07
in the HIV-uninfected group, the proportion of nonresponders
(12%) was higher than has been reported in previous studies,
which have reported reactive immune responses in 92%–97%
of persons [33, 34].
Predictors of vaccine response. The logistic model for
achievement of reactive NTs did not reveal statistically signif-
icant predictors. However, the point estimates tended to show
a better response in patients who were receiving successful
cART. This effect was reinforced by the linear regression model
of NT, in which HIV RNA levels !50 copies/mL and higher
CD4 cell counts at the time of 17DV administration were as-
sociated with a better primary immune response. In addition,
suppressed plasma HIV RNA levels and higher CD4 cell counts
at the time of NT determination were highly associated with
a better vaccine response. A subgroup of patients with initially
nonreactive NTs had reactive NTs during follow-up, after they
commenced cART and had consecutive undetectable HIV RNA
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Table 2. Linear regression model of neutralization titer levels and baseline parameters.
Characteristic
Univariable analysis Multivariable analysis
Coefficient (95% CI) P Coefficient (95% CI) P
HIV-RNA level, !50 copies/mL 0.24 (0.04–0.43) .02 0.18 (0.01 to 0.38) .06
CD4 cell count (square rooted) 0.02 (0.00–0.04) .04 0.02 (0.00–0.04) .04
Nadir CD4 count before receipt of 17DV 0.01 (0.02 to 0.01) .4 …
Receipt of triple-drug ART 0.18 (0.02 to 0.38) .07 …
CDC HIV infection classification (B/C vs. A) 0.02 (0.19 to 0.23) .8 …
Age (per 10-year increase) 0.09 (0.00–0.19) .05 0.08 (0.02 to 0.19) .1
Female sex 0.15 (0.05 to 0.35) .2 0.22 (0.03–0.42) .03
Chronic hepatitis B or C 0.16 (0.42 to 0.11) .2 0.22 (0.47 to 0.03) .08
Originally from country where yellow fever is endemic 0.14 (0.06 to 0.34) .2 …
Receipt of 17DV twice (compared with receipt of 17DV once) 0.07 (0.19 to 0.32) .6 0.05 (0.22 to 0.32) .7
Other live vaccine used 0.05 (0.23 to 0.14) .6 …
NOTE. ART, antiretroviral therapy; CDC, Centers for Disease Control and Prevention; 17DV, yellow fever vaccine.
levels—a phenomenon that, to our knowledge, has never before
been described. By contrast, most of the 11 patients who ex-
perienced a rapid decline to nonreactive NTs 5 years after
vaccination did not take cART, and their HIV RNA levels were
not suppressed at the time that they received 17DV. These
findings indicate that successful cART leading to suppression
of HIV replication and decreasing chronic immune activation
improves the initial response to 17DV and is associated with
durability of reactive titers during follow-up.
In our study, female subjects developed higher NTs than did
male subjects. This finding requires confirmation, because it is
in contrast to previous studies, which have reported better im-
mune responses after receipt of 17DV in HIV-uninfected male
subjects [35], and a recently published study reported no sex-
based differences [36].
In summary, in our study, markers of lower HIV replication
and less profound immunodeficiency were associated with a
better immunologic vaccine response. However, as in smaller
studies, we could not define a threshold CD4 cell count that
was predictive of a protective vaccine response with high
certainty.
Safety. Life-threatening 17DV-associated viscerotropic and
neurotropic disease have occurred in HIV-uninfected individ-
uals [14–19], with an estimated incidence of 1 case per 400,000
doses of yellow fever vaccine [17]. Because the incidence of
viscerotropic and neurotropic disease among immunocompro-
mised individuals is unknown, the safety of 17DV in HIV-
infected patients is of special concern. One report from Thai-
land described a fatal case of meningoencephalitis that occurred
shortly after yellow fever vaccination in an adult with previously
undiagnosed HIV infection and a CD4 cell count of 108 cells/
mm3 [6]. By contrast, serious adverse reactions were not ob-
served in 100 asymptomatic HIV-infected military employees
who received yellow fever vaccination before the introduction
of routine HIV screening [10], in 31 HIV-infected patients
before the availability of cART [4], and in 32 HIV-infected
patients from 4 studies conducted during the cART era [5, 7,
9, 11]. On the basis of these limited data, most experts rec-
ommend consideration of 17DV for HIV-infected patients at
true risk if the CD4 cell count is 1200 cells/mm3 [37].
In the present study, we found no SAEs after receipt of 17DV
in 102 HIV-infected participants. More than three-quarters of
these patients had CD4 cell counts 1350 cells/mm3 at the time
of vaccination, and only 7 patients had CD4 cell counts !200
cells/mm3at the time of vaccination. Because no SAEs occurred
among the 102 yellow fever vaccinees after HIV infection had
been diagnosed, we could exclude an incidence higher than 3%
at the 95% confidence level. Our findings are, therefore, in line
with current recommendations. However, the number of stud-
ied HIV-infected individuals, including those in our study, is
too small to exclude a low but relevant risk of SAE, even among
patients without moderate-to-severe immunodeficiency. There-
fore, careful obtainment of prevaccination information and
postvaccination surveillance are indicated for all HIV-infected
patients receiving 17DV.
Limitations of the study. The main limitation of this study
is its retrospective design in a prospective cohort. This did not
allow systematic determinations of NT after 17DV. Our com-
parison group, which was from the study by Niedrig et al. [21],
was considered to HIV negative, although serologic testing was
not performed before 17DV administration. However, these
individuals were asked by questionnaires about possible HIV
infection. Unfortunately, additional characteristics (except age)
were not available from this group for detailed comparison.
Another limitation is the use of antibody response to the vac-
cination as the end point. This is only a surrogate marker of
protection against yellow fever. However, studies that use the
incidence of yellow fever among travelers as the end point are
not possible, and use of the NT as a surrogate is widely accepted.
Recommendations. Our findings reinforce current rec-
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ommendations [37] about the safety of 17DV in HIV-infected
patients with CD4 cell counts 1350 cells/mm3 and possibly in
those with counts 1200 cells/mm3. However, a low risk (up to
3%) of SAEs cannot be excluded, and a surveillance system of
17DV in HIV-infected vaccines is required to monitor possible
rare SAEs.
Regarding immunogenicity, patients who are not receiving
cART and who have CD4 cell counts !350 cells/mm3 should
preferably postpone receipt of 17DV until the plasma HIV RNA
level is undetectable, to attain a more vigorous vaccine response.
Given the high proportion of individuals with nonmeasurable
primary immune response, we recommend determination of
NTs from 1 month up to 1 year after receipt of 17DV. In the
event that NTs are nonreactive, revaccination should be
considered.
The recommendation of a booster vaccination every 10 years
in nonimmunocompromised travelers [38] is probably not suf-
ficient for HIV-infected individuals, given their possible more
rapid decrease in NTs. NT determination or even revaccination
should be considered after 2–5 years in the event of potential
exposure. Clearly, more prospective data are required to cor-
roborate our recommendations.
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